Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$258,366Cash on Hand
0.4mo Cash Runway
Follow PPCB by emailGet an email when PPCB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PPCB, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 29, 2026 ·
Listing Received a Nasdaq notice on October 23, 2026 for non-compliance with the $1.00 minimum bid price rule, with no compliance period due to a reverse split in the prior year. Delisting is set for November 2, 2026 unless the company appeals by October 30, 2026, and it intends to appeal. Form 8-K · SEC filing
Sep 25, 2026 ·
Annual report for the period ended Jun 30, 2026 Form 10-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
PPCB holds $258,366 in cash and short-term investments (as of Sep 30, 2026) and burns about $1.8M/quarter from operations,
an estimated runway of 0.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:63 · High
Cash runway 0 months +40
S-1 registration (Oct 2026) +8
Going-concern doubt in the latest 10-Q +15It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the issue date of this Quarterly Report.10-Q, Nov 2026
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PPCB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.